Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

SEMAX (INTRANASAL)

Semax as a nasal spray.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Amino acid sequence

MEHFPGP
7 residues
Molecular formula
C₃₇H₅₁N₉O₁₀S
Average mass
813.9 Da
CAS number
80714-61-0
Registry
PubChem CID 9811102
Formula, mass and identifiers from PubChem CID 9811102. Mass recomputed from the sequence.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Semax (Intranasal) is the clinically preferred nasal-spray formulation of the nootropic peptide Semax, optimized for rapid, direct transport into the brain.

What problem it targets: It targets acute mental exhaustion, attention lapses, complex cognitive workloads, memory recall deficits, and sluggish mental processing speed.

What It Does

• Direct olfactory brain transport: Bypasses the systemic bloodstream and blood-brain barrier, reaching neural target sites within minutes of nasal application.

• Ignites rapid focus and mental processing: Quickly elevates BDNF and dopaminergic activity, transforming scattered thinking into sharp, sustained concentration.

• Shields neurons against cognitive burnout: Promotes cerebral circulation and protects brain cells from oxidative exhaustion during prolonged study or demanding work hours.

• Realistic expectations: Effects on focus, motivation, and mental clarity emerge within 5 to 15 minutes and last 4 to 6 hours. Excellent for on-demand cognitive enhancement without jitteriness.

Reconstitution

Vial sizeBAC water or SolventConcentrationNote
5 mg+ 5 mL sterile saline1 mg/mL1 spray = 100 mcg (100 µL)
10 mg+ 10 mL sterile saline1 mg/mL1 spray = 100 mcg (100 µL) (10 mL nasal spray bottle)

Protocol

PhaseFrequencyDoseNotes
StandardDaily AM200–400 mcg1–2 sprays per nostril, alternating sides. 100 µL @ 1 mg/mL = 100 mcg per spray.
HigherDaily AM600 mcg3 sprays per nostril, alternating sides. Or split AM + early afternoon to reduce nasal irritation.
Off1–2 weeks–Tolerance prevention. 5-day-on / 2-day-off variant also community-standard. Cycle: 2–4 week blocks, 1–2 weeks off. Timing: AM intranasal, calibrate sprays with the supplier’s nasal pump (standard 100 µL per actuation) before clinical use. Evidence: Russian-approved (stroke/cognition); no Western RCT. By sex: Unisex nootropic / neuroprotective (intranasal), dose by protocol, no sex effect. Avoid in pregnancy.

Handling & Stacking

Injection site
  • Intranasal: 1–2 sprays per nostril, alternating sides each dose.
  • Use a calibrated nasal pump (100 µL/spray, 100 mcg per spray at this recon) and tilt head slightly back during instillation.
  • For SubQ injection, see the Semax page.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted in saline: 36–46°F.
  • Best used within 21 days.
  • Discard if cloudy or particulate.
  • Community runs Semax nasal spray about ~1–2 weeks in plain saline (or ~3–4 weeks if made with bacteriostatic water) refrigerated at 36–46°F and dark, and it's worth leaning to the shorter end since Semax's N-terminal methionine oxidizes; it's community convention, not published data.
Side effects
Headache (first 1–3 days, resolves). Irritability if stacked with stimulants.
What to expect
  • Mental clarity and focus often within hours of first dose.
  • Sustained cognitive enhancement builds over 2–4 weeks.
  • Brief headache in days 1–3 is normal.
  • Supply math 5mg → 4 vials | 10mg → 2 vials (4-wk @ 600 mcg × 7/wk)
Pairs well with
Selank (anxiolytic + cognitive synergy); BPC-157 (neurorepair); Alpha-GPC or Citicoline (choline source prevents headache)
Avoid
MAOIs. Active psychosis / mania
Approved drug
  • There is no FDA-approved cognitive enhancer, no drug is approved for boosting focus or memory in healthy people (stimulants are approved only for ADHD/narcolepsy).
  • Semax’s Russian approval does not apply in the US.

Safety & Patient Education

Labs
Compound-specific: CBC + CMP baseline; no compound-specific markers routinely required
References
PubMed · thepeptidereport